Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia

The Food and Drug Administration currently approves the combination of hypomethylating agents (HMA), azacytidine or decitabine with venetoclax (VEN) for acute myeloid leukemia (AML) patients aged more than 75 years and for patients unsuitable for intensive chemotherapy. The risk of fungal infection...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Simona De Gregori, Eleonora Gelli, Mara Capone, Giulia Gambini, Elisa Roncoroni, Marianna Rossi, Claudia Patricia Tobar Cabrera, Gianluca Martini, Ludovica Calabretta, Luca Arcaini, Riccardo Albertini, Patrizia Zappasodi
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	MDPI AG 2023-06-01
Cyfres:	Pharmaceutics
Pynciau:	acute myeloid leukemia elderly patients venetoclax posaconazole HPLC-MS/MS dose adjustment
Mynediad Ar-lein:	https://www.mdpi.com/1999-4923/15/6/1680
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!